Dr. Sandy Srinivas explains how age, comorbidities and medications influence personalized prostate cancer treatment decisions ...

A new randomized clinical trial found that men with localized, intermediate‑risk prostate cancer recovered faster and ...

Patients with up to 20 brain metastases demonstrated significantly improved daily and neurocognitive functioning with ...

Top cancer specialists are urging men to look past the common symptoms of aging and recognize these critical warning signs. It’s often said that if you have your health, you have everything, and there ...

The MarketWatch News Department was not involved in the creation of this content. MINNEAPOLIS, March 25, 2026 /PRNewswire/ -- Francis Medical, Inc., a privately held medical device company, announced ...

Primary endpoint analysis at 1 year showed better maintenance of erectile function and pad-free continence with TULSA than with robotic radical prostatectomy. Peri-procedural metrics favored TULSA, ...

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...

Prostate cancer is one of the leading causes of cancer-related death in men, and some experts project the number of cases to rise over the coming decades. But in a recent Urologic Oncology article, ...

Prostate cancer is the most common cancer to affect American men, besides skin cancer. The American Cancer Society estimates that 1 in 8 men will be diagnosed with prostate cancer at some point in ...

HDR-BT was significantly associated with increased biochemical failure risk and acute grade 2 or higher genitourinary adverse events. In men with intermediate-risk prostate cancer, stereotactic body ...

The American Cancer Society reports that about one in eight men will be diagnosed with prostate cancer in their lifetime. The average age of men who get diagnosed is 67. Today, less than 1% of the 3.5 ...

High-risk localized prostate cancer treated with neoadjuvant LHRH agonist/antagonist and enzalutamide plus the glucocorticoid receptor antagonist relacorilant versus placebo. This is an ASCO Meeting ...